Sensitivity or sensitivity to Lopinavir or Ritonavir or recombinant IFN-β1b, including, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome. Use of drugs that are contraindicated with lopinavir/ritonavir and should not be substituted or discontinued during the study period, such as inhibitors CYP3A Pregnancy-Eligible female participants of childbearing age are tested for pregnancy before enrolling in the study HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs. Hemoglobin under 8 Known heart failure EF under 50% According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or prisoners, are excluded from the study.

Sensitivity or sensitivity to Lopinavir or Ritonavir or recombinant IFN-β1b, including, toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema or angioedema syndrome. Use of drugs that are contraindicated with lopinavir/ritonavir and should not be substituted or discontinued during the study period, such as inhibitors CYP3A Pregnancy-Eligible female participants of childbearing age are tested for pregnancy before enrolling in the study HIV infection is known to cause concern about the resistance to lepinavir / ritonavir if used in combination with other anti-HIV drugs. Hemoglobin under 8 Known heart failure EF under 50% According to the 31st National Guide, all vulnerable groups, such as the mentally disabled, emergency patients, or prisoners, are excluded from the study.